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Cross resistanceMultidrug resistance bacteria are a major concern worldwide. These pathogens cannot be treated with conven-
tional antibiotics and thus alternative therapeutic agents are needed. Antimicrobial peptides (AMPs) are consid-
ered to be good candidates for this purpose. Most AMPs are short and positively charged amphipathic peptides,
which are found in all known forms of life. AMPs are known to kill bacteria by binding to the negatively charged
bacterial surface, and in most cases cause membrane disruption. Resistance toward AMPs can be developed, by
modiﬁcation of bacterial surface molecules, secretion of protective material and up-regulation or elimination
of speciﬁc proteins. Because of the general mechanisms of attachment and action of AMPs, bacterial resistance
to AMPs often involves biophysical and biochemical changes such as surface rigidity, cell wall thickness, surface
charge, as well as membrane and cell wall modiﬁcation. Here we focus on the biophysical, surface and surround-
ing changes that bacteria undergo in acquiring resistance toAMPs. In additionwediscuss the question ofwhether
bacterial resistance to administeredAMPsmight compromise our innate immunity to endogenous AMPs. This ar-
ticle is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
© 2015 Published by Elsevier B.V.1. Introduction
The ﬁght between bacteria and man, once thought to be at its end
when antibiotics were discovered, has gained much attention in recent
years. The enhanced and unregulated use of antimicrobials has increased
the occurrence of bacteria resistant tomultiple antibiotics [1,2], thus urg-
ing the research community to develop new antibacterial agents. One of
the most promising strategies explored is the use of antimicrobial pep-
tides (AMPs) [3–6]. AMPs are hydrophobic and amphipathic short pep-
tides, which in most cases have a net positive charge [4,7]. Initially
AMPs were found in invertebrates [3] and later in all known forms of
life including humans [8,9], where they serve as part of our innate im-
mune system [5,10,11]. AMPs rapidly neutralize a broad range of mi-
crobes, both Gram-positive and Gram-negative, mainly through
binding and perturbing their cell envelope, which contains lipoteichoic
acid (LTA) or lipopolysaccharide (LPS) respectively, as well as their cyto-
plasmic membranes [5,6,12]. This makes AMPs promising candidates in
the quest to ﬁnd new and better antimicrobial agents [13].
It is believed that the chemical and physical characteristics of AMPs
such as a positive net charge secondary structure and amphipathic na-
ture are important for their antimicrobial activity [6,14–16]. For exam-
ple, in the case of Gram-negative bacteria, due to their net positive
charge, AMPs have high afﬁnity to the negatively charged LPS, andial Resistance to Antimicrobial
.then can displace divalent cations that are naturally bound to it. Howev-
er, it has been shown that some AMPs speciﬁcally bind oprI, a lipopro-
tein of Pseudomonas aeruginosa, located on the outer membrane and
suggested to serve as an AMP receptor. OprI is important for cell wall in-
tegrity and has homologs in other Gram-negative bacteria [17].
The binding of AMPs to the bacterial surface causes a local interfer-
ence with the outer membrane and enables peptides to traverse it.
When reaching the inner membrane, AMPs can function either without
causing membrane disruption by penetrating the cell and affecting cy-
toplasmic components such as DNA andDNA-polymerase [18]. Alterna-
tively, AMPs can function in membrane disruptive manner thus
impairing cell integrity [18]. Various mechanisms were suggested for
themembrane disruptive activity of AMPs [5,6,10,19]. Themainmodels
include: (1) the barrel-stave model — peptides assemble to form pores
with their hydrophobic surfaces facing themembrane core [20]; (2) the
carpetmodel— peptides bind to themembrane in a carpet-likemanner.
When a threshold concentration has been reached, they act as a deter-
gent and disrupt the membrane [10,21] and (3) the toroidal model —
peptides form transient pores composed of peptides and lipids' head
groups [22,23]. These pores were suggested to be as one of the stages
in the carpet mechanism [5].
Bacteria however, have evolved mechanisms to counteract AMPs.
There are two main types of resistance, (i) induced resistance, caused
by a transient induction of bacterial systems that help the bacteria
cope with AMPs, and (ii) constitutive resistance as a result of genetic
changes [24,25]. Currently, there are several putative mechanisms
known for bacterial resistance to AMPs [26–29]: remodeling of the
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able [30–35], modulation of host immunity gene expression in order
to suppress the release of native AMPs [36,37], bioﬁlm formation [38,
39], proteolytic degradation of AMPs by peptidases and proteases [40,
41], efﬂux pumps that expel the AMPs [27,42,43], and trapping mole-
cules [44–46] and vesicles [47] that capture the peptides and prevent
them from reaching the bacteria.
In this review we focus on the mechanisms that affect the biophysi-
cal characteristics of the bacteria and bacterial surrounding such as cap-
sid and bioﬁlm, as well as biochemical changes of the outer surface,
including the regulation of some of these processes by two component
systems (TCSs).
2. Bacterial resistance to AMPs as a result of changes in bacterial
outer surface
The outer surface of Gram-positive and Gram-negative bacteria is
negatively charged due to LTA and LPS, respectively. AMPs on the
other hand, are hydrophobic, positively charged molecules, and there-
fore it is believed that AMPs are initially attracted to the bacterial surface
due to electrostatic interactions. In linewith this, it is assumed that neu-
tralization of the negative charge can reduce peptide binding to the bac-
terial surface, and will be further discussed. Note that several reviews
were published on this subject [26,48–51].
2.1. Extracellular polysaccharides
Extracellular polysaccharides are polymers produced by some
Gram-positive and Gram-negative bacteria. When covalently linked to
the cell wall they are termed capsule [28]. The question of whether or
not a capsule contributes to AMP resistance is still under debate [51].
There are some reports indicating that capsules cause AMP-resistance
[51–53]. For example,Klebsiella pneumoniaebacteriamutated in capsule
production are more susceptible to AMPs and bind better polymyxin B
(PmB) compared to the wild-type (WT) [54]. Moreover, PmB was
found to induce capsule production in these bacteria, and it was sug-
gested that the capsule serves as a shield toward AMPs, thus limiting
their interaction with the bacterial surface [55]. In addition, it was
shown that K. pneumoniae, Streptococcus pneumoniae and P. aeruginosa
tend to naturally release capsule polysaccharide (CPS) fractions into
the environment, which contributes to their resistance to AMPs. This se-
cretion is enhanced in the presence of PmB. Supernatant containing CPS
of these strains showed increased resistance in Escherichia coli strain
[54]. Moreover, the authors demonstrated that anionic CPSs but not cat-
ionic or neutral charged CPSs of S. pneumoniae, speciﬁcally bind dansyl-
PmB [54]. In Group B Streptococcus it was demonstrated that bacteria
mutated in capsule production did not demonstrate a higher suscepti-
bility to several tested AMPs [35]. To conclude, some studies have dem-
onstrated AMP resistance mediated by capsules and some show that
capsules do not change the resistance. We suggest therefore that
whether or not a capsule confers AMP resistance depends on the bacte-
rial species, and perhaps on the AMP itself.
2.2. Lipid modiﬁcations in bacterial membranes
2.2.1. Phosphatidylglycerol (PG) modiﬁcations
In Gram-positive bacteria, a gene encodes for a large membrane
protein mprF responsible for the addition of lysine or alanine to
phosphatidylglycerol (PG) to form lysyl-phosphatidylglycerol (LPG)
and alanyl-phosphatidylglycerol (APG), respectively [56], as well as
for the translocation of these products to the outer leaﬂet [56–58]. In
several studies, mprFmutants of Staphylococcus aureus were found to
be more susceptible to AMPs, which might suggest that the addition
of these amino acids to the membrane reduces susceptibility to AMPs
[59] (a detailed review regarding AMP resistance mediated by mprF
can be found in reference [60]). However, in another study it wasshown that there was no change in susceptibility of S. aureusmutants
tomprF for the tested peptides [35].
The membrane of S. aureus consists mostly of unmodiﬁed PG (38–
76% of the phospholipids), its dimer, diphosphatidylglycerol (DPG)
also known as cardiolipin (5–30%) and about 14–38% of LPG [58].
Some daptomycin (a lipopeptide) resistant S. aureus isolated strains
showed gain of function mutations in mprF and had a higher LPG con-
tent compared to the susceptible strains. These strains were found to
be more resistant to thrombin-induced platelet microbicidal proteins
(tPMPs), and showed a reduced net surface charge [61]. In line with
that, less daptomycin was bound to their surface compared to the
other strains, however the binding of classical AMPs was not examined
in this study [61]. In the Gram-negative bacteria P. aeruginosa, a homo-
log for MprF was found, which is responsible for the addition of alanine
to PG to form APG. This modiﬁcation resulted in increased resistance to
antimicrobial agents including the AMP protamine sulfate [62,72].
2.2.2. Changing the fatty acid composition
It was suggested that membrane lipid composition can affect
cell wall properties and change interactions with AMPs, and therefore
the susceptibility to these agents [63]. S. aureus strains resistant to
thrombin-induced platelet microbicidal protein 1 (tPMP-1), showed a
higher proportion of longer and more unsaturated fatty acids in the
membrane, as well as higher membrane ﬂuidity compared to the con-
trol, but no differences in phospholipid composition [64]. Daptomycin
resistant S. aureus isolated strains also showed a higher membrane ﬂu-
idity compared to the control [65–67]. Nevertheless, one study reports
on a correlation between membrane ﬂuidity and the level of resistance
to AMPs [67]. Conversely, other AMP-resistant bacteria showed a higher
rigidity. Two S. aureus strains, one resistant to magainin 2 and the other
to gramicidin D, had a higher proportion of LPG in their cell membrane
compared to the control strain and bothmutants showed higher rigidity
and surface positive charge [68]. Enterococcus faecalis pediocin-resistant
strains showed a higher ratio of saturated and unsaturated fatty acids, as
well as, reduction in branched fatty acids in these strains compared to
the WT. These changes in fatty acid composition increase cell mem-
brane rigidity, and are thought to reduce the insertion of pediocin
(AMP) to the membrane [69]. In summary, membrane ﬂuidity is not a
direct indication for resistance to AMPs, and cell membrane can be
more or less ﬂuid in the context of the organism and the AMP.
Comparison of nisin resistant and susceptible strains of Listeria
monocytogenes revealed that the ratio of PG and DPG was higher than in
theWT. An in-vitro nisin binding assaydemonstrated that nisin binds bet-
ter to a lipid-monolayer derived from the WT than the resistant strain
[70]. Other studies reported that nisin resistant L. monocytogenes strains
had a greater proportion of saturated fatty acids whereas the WT had
more unsaturated ones [71]. In E. faecalis, a Gram-positive bacterium,
pediocin-resistant strains had more LPG and phosphoethanolamine
(PEA) in their cell membrane compared to the WT [69]. AMP resistance
in Salmonella enterica Typhimurium, a Gram-negative bacterium, was
found to be mediated by increased levels of DPG and palmitoylated
acyl-phosphatidylglyceroles in the inner leaﬂet of the outer membrane,
which is mainly composed of glycerophospholipids. This palmitoylation
is conducted by the protein pagP and regulated by the two-component
system PhoPQ [72] (Fig. 1).
2.2.3. In-vitro studies
An in-vitro study examined the effect of binding and pore formation
ability of AMPs on large unilamellar vesicles (LUVs) composed of differ-
ent proportions of lipids. LUVs were generated containing 1-palmitoyl-
2-oleoyl-phosphatidylglycerol (POPG) and different concentrations of
either zwitterionic Gln-PE or positively charged Lys-PE. It was shown
that while increasing the concentration of the Gln-PE in the membrane
does not change the level of bound cecropin A and mastoparan X
(AMPs), the increase of the Lys-PE in the membrane reduced the bind-
ing. Pore formation assay revealed that increasing concentration of Lys-
Fig. 1. Outer membrane of Gram-negative bacteria (S. enterica): schematic representation of the inner and outer leaﬂets of the outer membrane. The outer leaﬂet consists of LPS and PG.
The LPSmoiety consists of Lipid A-di-glucoseamine linked to fatty acids, and is themajor component of the outer leaﬂet. This Lipid A is linked to sugars of the core (colored hexagons), and
the O-antigens (black-lined hexagons). The inner leaﬂet on the contrary contains PG, DPG and LPG or APG [62,72,197].
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cecropin A and mastoparan X, while 10% of Gln-PE increased pore for-
mation [73].Fig. 2.D-alanylation of LTA. Illustration of D-alanylation of LTA of S. aureus. D-ala is added
to the repeated unit of the LTA by the enzyme DltA, and contributes to bacterial resistance
[198,199].2.3. LTA D-alanylation of LTA in Gram-positive bacteria
The surface of Gram-positive bacteria consists of the cytoplasmic
membrane, a thick peptidoglycan layer and lipoteichoic acid (LTA). It
has been reported that D-alanylation of the LTA contributes to bacterial
resistance to AMPs [74–76]. It was found that the dlt operon is respon-
sible for the incorporation of D-alanine (D-ala) into teichoic acid,
which results in an increase in the positive charge of the bacterial sur-
face. Mutants of dltA, the gene encoding a D-alanyl carrier protein ligase
(that adds D-ala to the Gro-P moiety of the LTA) showed increased sus-
ceptibility to AMPs, whereas overexpression of this gene confers in-
creased resistance [77] (Fig. 2, Table 1).
Reducing the net negative charge of the LTA is considered to contrib-
ute to the reduction of electrostatic interactions between the positively
charged AMPs and the negatively charged bacterial surface, thus reduc-
ing susceptibility [34,76,78,79]. However, recent experimental data on
Group B Streptococus (GBS) indicate that there is no signiﬁcant change
in the amount of peptide bound to the dltAmutant bacteria compared
to the WT. It was proposed that the higher resistance observed in the
WT compared to the dltAmutant is due to an increase in cell wall den-
sity and reducedAMPpenetration [35], i.e. the addition of D-ala to Gro-P
moiety of the LTA does not change the amount of bound peptide, but
rather serves as a shield that prevents peptides from entering the bacte-
ria. No difference in cell wall thickness was found in this study [35] as
well as in other studies [35,61,80]. However, several studies showed a
thicker cell wall of different AMP-resistant bacteria [81,82], which sug-
gests that cell wall thickness might be, but is not necessarily, correlated
with resistance. Importantly, the D-alanylation of the LTA contributes to
the resistance of bacteria to only some AMPs [35] and so far, other
known modiﬁcations of the LTA (e.g. the addition of phosphocholine
and glycosylation) were not tested for their effect on resistance to anti-
microbial peptides [83].2.4. Surface modiﬁcations of Gram-negative bacteria
The surface of Gram-negative bacteria is complex and covered
with several constituents such as LPS, proteinaceous curli ﬁbers, cel-
lulose and capsules [84–88]. LPS, which is thought to be the main
surface element, consists of a conserved lipophilic component,
lipid-A, linked with different polysaccharides or oligosaccharides,
giving it a net negative charge. The LPS composition is dynamic; it
may be modiﬁed and is found to be diverse in length and composi-
tion among the different Gram-negative bacteria species [87]. This
unique structure, besides helping to maintain cellular equilibrium,
serves as a physical barrier and may provide protection against
Table 1
Details of the modiﬁcations and the enzymes responsible for the LPS modiﬁcations that are detailed in Figs. 2 and 3.
Gene Organism Protein function Reference
AlmG V. cholerae Adds glycine to the secondary acyl chain of the hexa-acylated Lipid A [29]
ArnT (orf5, PmrK, or ifbI) S. enterica, E. coli, P.
aeruginosa
Adds L-Ara4N (4-amino-4-deoxy-L-arabinose) to one or both of the phosphate groups of Lipid A [108,110]
ArnT ortholog F. tularensis subspecies
novicida
Adds galactosamine (GalN) to the phosphate substituent at the 1-position of Lipid A [110,113,193]
ArnT ortholog Bordetella pertussis Adds of glucosamine GlcN to both phosphate groups of Lipid A [110]
EptA (pmrC) H. pylory, S. enterica, E. coli Adds phosphoethanolamine (PEA) to the 4′ phosphate on Lipid A [99,101]
EptB S. enterica, E.coli Adds phosphoethanolamine (PEA) to the 3-deoxy-D-manno-octulosonic acid (Kdo) of the inner core [102]
LptA N. gonorrhoeae, Neisseria
meningitides
Adds phosphoethanolamine (PEA) to the 4′ phosphate on Lipid A [104,105,194]
LpxF H. pylory, F. tularensis Dephosphorylates Lipid A at position 4′ leaving unmodiﬁed hydroxyl group. [99,193]
LpxM E. coli Adds myristate (C14:0) to the myristate on the 3′-position of the glucosamine disaccharide base of
the Lipid A
[195]
LpxN V. cholerae Adds of a 3-hydroxylaurate (3-OH C12:0) to the myristate on the 3′-position of the glucosamine
disaccharide base of the Lipid A
[195]
LpxO S. enterica Adds hydroxyl group the 2′ position of the myristoyl residue at the 3′ position of the glucosamine
disaccharide base of the Lipid A
[72,107]
PagL S. enterica Removes 3-hydroxymyristate from position 3′ [72,196]
PagP S. enterica Adds palmitoyl group to PG on the outer membrane and Lipid A [72,196]
DltA S. aureus Adds D-alanine to the Gro-P moiety of the LTA [77]
MprF S. aureus Responsible for the addition of lysine and alanine to PG on the plasma membrane [56,60,62]
VraFG S. aureus AMP efﬂux pump [169]
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contribute to bacterial resistance to AMPs. The modiﬁcations of the
LPS depend on bacterial species and environmental conditions, andFig. 3. LipidA and inner coremodiﬁcations. The outer surface ofGram-negative bacteria ismostl
(iii) O-antigen (from the inside to the outside). The cartoon summarizes the modiﬁcations tha
resistance and susceptibility. Eachmodiﬁcation of the Lipid A and inner core are colored in a m
occur in all bacteria species, and they might be relevant to one or more bacterial species (a pa
refers to a structure of E. coli and S. enterica, but other Gram-negative bacteria might have an ait was shown that not all modiﬁcations are found in all bacteria spe-
cies [71]. Here we will discuss some of the changes in the outer sur-
face with respect to AMP resistance and susceptibility. Lipid A andy LPS. This LPS consists of three components (i) LipidA; (ii) core (inner and outer core); and
t take place on the Lipid A and the inner core, which were shown to be involved in AMP
atching color as the name of the enzyme responsible for it. Note that not all modiﬁcations
rtial modiﬁcation per species can be found in Table 1). In addition, the current illustration
ltered structures of Lipid A and inner core.
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summarized in Fig. 3 and Table 1.
2.4.1. Acylation and deacylation of Lipid A
Addition of an acyl chain to Lipid Awas found to contribute to bacte-
rial resistance to AMPs. PagP is a gene that encodes for an outer mem-
brane palmitoyl transferase in S. enterica Typhimurium [72]. This
enzyme adds additional palmitate (C16:0 acyl chain) to the Lipid A
moiety (Fig. 3) and this acylation is thought to increase the hydrophobic
interactions between the acyl chains in the Lipid A, thus increasing outer
membrane ﬂuidity [90–92]. S. enterica Typhimurium mutants in pagP
showed higher membrane permeability in response to AMPs compared
to the control strain, aswell as, Legionella pneumophilamutants in Rcp, a
PagP homolog that showed a higher susceptibility to C18G and PmB
[93].
To support the ﬁnding that Lipid A acylation contributes to bacterial
resistance to AMPs, deacylation was found to increase bacteria suscepti-
bility to AMPs. PagL is an enzyme responsible for deacylation of Lipid A.
It is located on the outermembrane of several Gram-negative bacteria in-
cluding S. enterica Typhimurium, and removes R-3-hydroxymyristate
from position 3 of some Lipid A precursors [94]. It was found that pagL
is expressed upon PhoPQ activation but no deacylation of Lipid A was
detected under these conditions. Moreover, it was demonstrated
that pagL is latent in the WT, and the regulation of the latency involves
aminoarabinose modiﬁcations of the Lipid A regulated by pmrA.
Therefore, the pagL null mutation did not change cell permeability to
ethidium compared to the WT [94]. However, permeability of pmrA-
pagL double mutant was lower compared to pmrA mutant, that lacks
aminoarabinose modiﬁcations on the Lipid A, which indicates that
deacylation by PagL increases the permeability of themembrane. In addi-
tion, it was shown that a WT strain containing a non-latent pagL vector
possesses an increased susceptibility to various antimicrobial agents com-
pared to the WT [95,96]. However, investigating the effect of pmrA/pagL
and pmrc/pagL double mutants on the susceptibility to PmB showed in-
creased susceptibility to this AMP in the double mutants compared to
pmrA and pmrC single mutants [97]. pagLmutant did not show increased
susceptibility compared to theWT, whichmight suggest that deacylation
of Lipid A is important to PmB resistance under certain conditions [97].
2.4.2. Addition of glycine to Lipid A
It was found that AlmEFG operon is involved in glycine and diglycine
addition to the LPS of the Gram-negative bacteria Vibrio cholerae. This
modiﬁcation confers polymyxin resistance in these species. The AlmEFG
operon has some sequence homology with complexes involved in D-
alanylation in Gram-positive bacteria [29,98]. This modiﬁcation process
requires three proteins, AlmE activates glycine and transfers it to the
carrier protein AlmF. The glycine is then transferred to AlmG which in
turn transfers the glycine to the Lipid A [29]. However, it was not yet re-
ported on how this modiﬁcation confers V. cholerae resistance to poly-
myxin, and whether this system is present in other Gram-negative
bacteria (Fig. 3).
2.4.3. De-phosphorylation, hydroxylation and addition of
phosphoethanolamine (PEA) to Lipid A
Studies have shown that de-phosphorylation of Lipid A contributes to
resistance against AMPs. It was shown thatHelicobacter pylori possesses a
protein called LpxE that is responsible for the de-phosphorylation of
Lipid A at position 1. This de-phosphorylation allows the addition of
phosphoethanolamine (PEA) by EptA (PmrC), a PEA transferase. In addi-
tion, LpxFwas found to dephosphorylate Lipid A at position 4 leaving an
unmodiﬁed hydroxyl group [99]. LpxE and LpxFmutants were shown to
possess a higher susceptibility to PmB. In addition, a Lipid A fully phos-
phorylated at positions 1 and 4 was shown to bind PmBmore efﬁciently,
rendering these bacteria more susceptible to PmB [99]. It was initially
found that the LPSof PmB resistant E. coli contains two to three fold higher
amounts of PEA compared to the WT [100]. Addition of PEA to the LPS isalso thought to change the net negative charge of the LPS and by that con-
tributes to the electrostatic repulsion of the positively charged AMPs [27].
PEA attachment can occur either on the phosphate group of the Lipid A or
of the inner core oligosaccharides (3-deoxy-d-manno-octulosonic acid,
also known as Kdo). In E. coli and S. enterica Typhimurium, these modiﬁ-
cations are conducted by two distinct enzymes. A pmrA-regulated PmrC
(EptA) is responsible for the PEA incorporation into the Lipid A [101],
while the enzyme EptB couples the PEA moiety to the Kdo of the inner
core polysaccharide [102]. However, EptBwasnot reported to be involved
in antimicrobial resistance, and turned out to be regulated by other pro-
teins rather than PmrA [103] (Fig. 3).
In other Gram-negative bacteria such as Neisseria gonorrhoeae and
meningococcal bacteria, the gene lptAwas found to encode for a protein
with a similar activity as PmrC [104,105]. Mutants in the pmrC of
S. enterica Typhimurium and in lptA of N. gonorrhoeaewere more sensi-
tive to PmB compared to theWT [105]. In addition, an in vivo studywith
N. gonorrhoeae showed that the addition of PEA to lipooligosaccharides
(analogous to LPS in Neisseria strains) confers a survival advantage
compared to lptAmutant in humans and mice [106]. It was found that
pmrA mutants, which lack the aminoarabinose and PEA modiﬁcations
on the Lipid A, are more permeable to ethidium, which suggests that
thesemodiﬁcations are involved in generating a robust permeation bar-
rier [96]. However PmrA also regulates other genes that might affect
membrane permeability. Hydroxylation of the myristate at position 2
on the Lipid A in S. enterica Typhimurium by LpxOwas shown to reduce
permeability of themembrane and suggests that this hydroxylation can
increase the hydrogen bond between neighboring molecules of LPS,
which contributes to the outer membrane stabilization [107] (Fig. 3).
2.4.4. Addition of amino-sugars to Lipid A
There are several amino-sugars that are added to the Lipid A moi-
ety and are known to contribute to AMP resistance. These include
(i) aminoarabinose, (ii) glucosamine, and (iii) galactoseamine (Fig. 3).
(i) Addition of 4-amino-4-deoxy-L-arabinose (L-Ara4) to the phos-
phate group of the Lipid A correlated with acquired resistance to
AMPs. L-Ara4 addition is done by ArnT, an enzyme regulated by
PmrAB TCS [108]. The addition of L-Ara4 causes reduction of the
net negative charge of the LPS, which is thought to reduce the at-
tachment of positively charged AMPs, due to electrostatic repul-
sion [25,94,100]. In addition to its direct role in AMP resistance,
the addition of L-ara4 to LPS has a regulatory effect on other pro-
cesses related to LPS, such as the deacylation of Lipid A by pagL
(as described in Section 2.4.1 above) [95,96] and LPS export. It
was found that L-ara4 synthesis is essential for bacteria viability
since it is important for proper export of LPS molecules to the
outer membrane of Burkholderia cenocepacia [109]. It is possible
that part of the AMP-resistance that is related to L-ara4 is due to
its regulatory effects and not to direct effects of this modiﬁcation.
(ii) It has been reported that LPS undergoes amodiﬁcationwhere glu-
cosamine is added to the two phosphate groups of the Lipid A in
several species of Bordetella genus by ArnT homolog [110,111].
This modiﬁcation was found to confer resistance to AMPs, and re-
duce outer membrane perturbation by EDTA [112].
(iii) Addition of galactosamine to Lipid A was ﬁrst discovered in
Francisella tularensis Holarctica and Francisella novicida, and is
done by ArnT homolog [113–115]. It was found later that in
order for the galactosamine addition to occur, deacetylation of
the Lipid A needs to take place. This deacetylation is done by
NaxD, and NaxD mutants were more susceptible to PmB com-
pared to the parental strain [116].
2.4.5. Changing the length of O-antigen
To date, there is no conclusive evidence of whether the existence
and length of the O-antigen moiety of the LPS affects AMP resistance.
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O-antigen production is more sensitive to PmB compared to the WT
strain. Thismutant has a deletion inwbaP, a gene responsible for the ad-
dition of phosphogalactose to undecaprenyl-phosphate, a step neces-
sary for O-antigen biosynthesis in this strain. However, this strain was
still infectious and causes gut inﬂammation in mice models [117]. On
the other hand, in F. tularensis it was shown that the absence of O-
antigen did not cause a higher susceptibility to AMPs [118].
In addition, there is no conclusive answer of whether the length of
the O-antigen in S. enterica Typhimurium affects resistance to AMPs.
O-antigen length in these bacteria is deﬁned by WZZst and fepE
(WZZfepE) genes regulated by PmrAB TCS [119]. WZZst and fepE code
for a long O-antigen and a very long O-antigen, respectively [120,121].
Some claim that S. enterica Typhimurium mutants in FepE showed
higher susceptibility to PmB [119], while others showed no change in
susceptibility [122].
3. Modiﬁcations of the bacterial outer surface that inﬂuence peptide
properties
Binding of AMPs to the LPS could change their chemical properties. It
was shown [89] that a 12-mer peptide K5L7 has lower antibacterial ac-
tivity compared to its diastereomer 4D-K5L7 in which four L-amino
acids were replaced with their enantiomers, D-amino acids. Nonethe-
less, when comparing the effect of these peptides on PG and phosphati-
dylethanolamine (PE) vesicles, an increase in the permeability of the
corresponding vesicles was found for both. Furthermore, they strongly
bind LPSwith a similar afﬁnity; however each one of themwas affected
differently by the LPS. Both peptides have undeﬁned structure in solu-
tion, but in LPS, K5L7 became aggregated whereas 4D-K5L7 did not.
These results suggest that membrane binding is important for AMP ac-
tivity, but it is not the only factor that affects the permeating activity of
the peptides. It might also suggest that peptides can change their prop-
erties depending on the lipid they are bound to, and might explain the
different effectiveness of peptides onGram-positive and negative bacte-
ria. Later work also supports this hypothesis [63].
4. Mechanisms of bacterial AMP resistance in bioﬁlms
Bacterial bioﬁlms are a colonization of bacteria on either a biotic or
abiotic surface, where they form three dimensionalmulti-cell structures
in which bacteria are embedded in an extracellular matrix (ECM) com-
posed of polysaccharides, DNA and proteins. Bioﬁlms can be well struc-
tured and involve quorum sensing and formation of molecules that
mediate migration of cells within the bioﬁlm and formation of speciﬁc
structures as seen in P. aeruginosa [123,124]. Bioﬁlms are important
for bacterial survival in their natural environments [125], and protect
the bacteria from the immune system and antibiotics including AMPs
[126,127]. Bacterial susceptibility to AMPs in bioﬁlm was lower com-
pared to the planktonic state [128,129], however bioﬁlm-resistance to
AMPs was not extensively studied compared to other antimicrobial
agents. Furthermore, no speciﬁcmechanisms for AMP-resistance in bio-
ﬁlm were discovered. Some of the putative mechanisms of resistance
against antimicrobial agents in bioﬁlms can theoretically be applied to
AMPs and are therefore discussed in the following sections. A detailed
review about resistance mechanisms to antibiotic in bioﬁlm has been
published recently [130].
4.1. Creation of sub-populations in the bioﬁlm
P. aeruginosa bioﬁlms that were grown in a ﬂow chamber formed a
mushroom shaped structure, and two well distinguished subpopula-
tions were found in it [131]. When a bioﬁlm was treated with colistin,
there was a clear difference between the bacteria in the middle layer
and those on the outer layer. The bacteria in the middle of the colony
died while those on the outer layer were kept alive [131]. In addition,the bacteria on the outer surface and not in the middle were character-
ized with motility as was demonstrated after photo bleaching [131].
Resistant individuals were also found in bacteria with motility deﬁcien-
cies. However these bacteria were not placed on the outer part of the
bioﬁlm, but were randomly incorporated in it. This might suggest that
the motility is important for the arrangement of the different popula-
tions in the bioﬁlm, but not directly involved in AMP-resistance [131,
132]. Furthermore, pmr operon expression pattern as observed with
GFP was correlated to the two bacterial subpopulations [131]. Further-
more, cells of the different subpopulationswere characterized by differ-
ent metabolic levels whereas cells in the outer surface were more
metabolically active compared to the ones in the middle. This suggests
that metabolically active bacteria are more resistant to colistin [132].
4.2. A higher mutation rate
It was found that bacteria in bioﬁlm tend to have a higher mutation
rate compared to the planktonic bacteria. The higher mutation rate can
accelerate the natural occurring process of resistance to antimicrobial
agents [130]. The accelerated mutation rate was found to involve a re-
duced expression of DNA repair genes and mismatch repair system, as
well as, elevation in oxidative stress [130]. In addition, several studies
reported for a higher frequency of horizontal gene transfer in bioﬁlm,
which is another aspect that contributes to a highermutation rate [133].
4.3. Upregulation of efﬂux pumps
Efﬂux pumpswere shown to confer AMP resistance in several bacte-
rial strains in their planktonic state [27,42,43] and bioﬁlm state [132,
134]. It was reported that efﬂux pumps undergo upregulation in bioﬁlm
compared to the planktonic state [135–137]. In addition, MexAB-OprM
efﬂux pumps were found to be important for the development of toler-
ance to colistin in a sub-population of P. aeruginosa bioﬁlm [132]. A de-
tailed review about the role of efﬂux pumps in bioﬁlm resistance to
antibiotics can be found in reference [137].
4.4. Induction of TCSs within the bioﬁlm
P. aeruginosa resistant to colistin showed upregulation of pmr oper-
on genes, which was suggested to contribute to bacterial bioﬁlm toler-
ance due to LPS modiﬁcations [131,132]. It was also suggested that the
DNA that is foundas part of the ECMreduces the level of divalent cations
in the environment thus activating PhoPQ TCS and conferring resistance
to AMPs [38].
4.5. Diffusion in bioﬁlm
It is not clear whether bioﬁlm can reduce the diffusion rate of AMPs
and in so doing help to resist them. It was shown that the diffusion rate
of ﬂuorescein, a small molecule that does not interact with the bioﬁlm,
is not affected by the presence of a bioﬁlm. However, it was predicted
that the diffusion of large molecules will be inﬂuenced by the bioﬁlm
[138]. Periplasmic glucanwas found to confer resistance to several anti-
biotics in P. aeruginosa, in a bioﬁlm speciﬁc manner, where a mutant for
ndvB, a gene necessary for periplasmic glucan, was shown to be more
susceptible to these agents [139]. In this work the authors suggested
that glucans interact with the antibiotics, and therefore slow the
diffusion rate of these molecules. However, resistance to AMPs was
not checked in this respect. In addition, it was shown that
P. aeruginosa and K. pneumoniae bioﬁlms reduce the diffusion rate of
beta-lactam antibiotics only when beta-lactamase enzymes are present
within the bioﬁlms [130,140]. For more details on diffusion of antibi-
otics in P. aeruginosa bioﬁlms the following review is recommended
[141].
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TCSs are commonly used in bacteria to sense and respond to envi-
ronmental changes [142–145]. Many of the outer surface modiﬁcations
that were discussed above are a result of activation of such systems via
regulation of the expression of downstream genes as will be discussed
in the following section. TCSs consist of a membrane sensor that re-
ceives signals from the environment and transfers this information by
activating a transcriptional response regulator through phosphorylation
or de-phosphorylation [24,143,146–150]. In these systems, a receptor
(usually histidine kinase) is situated in the cytoplasmic membrane,
and is activated by an environmental signal. The sensor in turn phos-
phorylates a cytoplasmic protein that acts as a transcription factor.
The response involves activation of sets of genes such as virulence
genes, ion transporters and membrane-remodeling genes that help
the Gram-positive and Gram-negative bacteria to adjust better to the
environment within hours. Some of these TCSs are known to help bac-
teria cope with AMPs and are activated by them.
5.1. TCSs activation by AMPs
S. enterica PhoPQ TCS is known to be activated by low pH, low diva-
lent cation concentration and AMPs [151–153]. It has been shown re-
cently that peptides with a higher positive charge were more potent
in PhoPQ activation [15]. Studies on the mode of PhoQ activation by
AMPs suggest that they displace divalent cations that bind to a highly
acidic domain within the PhoQ [149,153–158], which corroborates the
ﬁnding that the more positively charged the AMP is, the more it tends
to activate the PhoPQ [15]. Surprisingly, a histidine-rich AMP with a
charge of only +1 under these conditions was highly potent in PhoPQ
activation [15]. This supports a second mechanism for removing diva-
lent cations and activation of PhoPQ by certain AMPs. In that case, histi-
dine, a known chelator for divalent cations, exerts this activity in the LPS
environment, reducing their concentration in the environment leading
to PhoPQ activation [15]. However, activation by different signals pro-
motes different responses [159]. PmrAB TCS is known to be activated
by high Fe+3 concentration and low pH [158]. In addition, there is a
crosstalk between these two TCSs, and PhoPQ activated gene pmrD en-
codes for a protein activator that activates pmrA, which in turn re-
presses pmrD expression [151]. These systems have homologous
systems in several Gram-negative bacteria, but the interaction between
them in different species can be different. For example in E. coli another
unknown bacterial system is involved in PmrAB activation in a PmrD
dependent manner [160]. Both PhoPQ and PmrAB were found to be es-
sential for the virulence of many bacteria species [143,161,162].
GraRS (ApsRS) is a well-studied TCS with respect to AMP resistance,
that is found in several Gram-positive bacteria such as S. aureus and
Staphylococcus epidermidis [163]. Similarly to PhoPQ activation in
Gram-negative bacteria, it is assumed that AMPs bind a highly negative
extracellular loop in the GraS (ApsS) sensor protein, and cause activa-
tion of this system [164]. GraRS was shown to crosstalk with another
bacterial system Stk1/Stp1, where Stk1 phosphorylates the response
regulator GraR, and thus enabling alanylation of the wall theichoic acid
(WTA) by dlt operon, which is regulated by GraRS TCS. S. aureusmutants
in the phosphorylation site of Skt1onGraR showed a similar reduced level
of alanine in the WTA [165]. However, Bacillus subtilis homolog for GraR,
BceR, does not undergo Skp1 dependent phosphorylation [165]. Other
TCSs in S. aureus were also reported to play a role in vancomycin resis-
tance. Such TCSs are WalKR, VraSR and AirSR (YhcSR) [166,167].
5.2. Genes activated by TCSs that are involved in AMP resistance
Upon activation, TCSs can activate tens and even hundreds of genes
[168,169]. Some of the genes activated by PhoPQ and PmrAB are able to
change the composition of the LPS and other surface elements and so
change their general surface thickness and charge, thus altering AMP'seffect on these bacteria [92,100,145,170]. For example, PhoPQ induces
pagP and pagL expression. pagP, as described before, encode for
acyltransferases which catalyze palmitoylation of lipid-A and
glycerophospholipids of the inner leaﬂet of the outer membrane [72,90].
On the other hand, pagL encodes a deacylase which removes a fatty acid
from the Lipid-A core [94]. This might involve changes in the thickness
and the hydrophobicity of the LPS [90,92] (Fig. 4). Other PhoPQ and
PmrAB activated genes are pmrE and pmrHJIFKLM operon that are in-
volved in LPS charge modiﬁcations [3,94,100,171–176]. Because these
systems induce genes that inﬂuence the hydrophobicity and charge of
the LPS, it is highly logic to assume that they contribute to resistance to-
ward AMPs. Indeed PhoPQ and PmrAB relevance to AMP-resistance was
demonstrated by showing that phoP-KO or pmrA-KO bacteria displayed
increased susceptibility to some AMPs (particularly PmB and colistin)
compared to the WT [13,177–183]. Despite extensive studies there are
still genes induced by these systems that have an unknown function
[184,185]. In addition, most of the work done was limited to certain
types of AMPs (particularly PmB, colistin and LL-37), which do not repre-
sent the major classical AMPs.
GraRS TCS consists of GraS — a sensor protein, GraR (ApsR) — a
response regulator and another accessory protein with an unknown
function, GraX (ApsX). Mutations in each of these three genes increase
susceptibility to AMPs [164,186]. GraRS is known to regulate the expres-
sion of mprF gene, dlt operon and vraFG operon [57,187], which are
known to be involved in AMP resistance. Overexpression of GraRS in
S. aureus caused higher resistance to vancomycin [163]. As previously
mentioned, MprF is responsible for the addition of lysine and alanine
to PG on the plasma membrane, DltA is involved in the addition of D-
ala to the LTA, and VraFG is an AMP efﬂux pump. In L. monocytogenes
a TCS named VirRS regulates dlt operon and mprF homolog, among
other genes [169] (Fig. 4).
6. Ways to overcome AMP resistance
Mammalian AMPs serve as part of the innate immune system, and
consist of two main groups, cathelicidins and the cysteine rich
defensins. Mutations in genes related to AMP production in humans
and mice led to frequent bacterial infections, while transgenic mice ex-
pressing high amounts of human defensin 5 were protected from cer-
tain bacterial infections [188]. All known mechanisms of bacterial
resistance to AMPs refer to general changes in bacteria properties that
allegedly can be applied to all AMPs. Therefore, there is an ongoing
debate as to whether the use of AMPs in the clinic can lead to bacteria
resistance to naturally occurring AMPs, and by that damage the activity
of the innate immune system against various pathogens [13]. Currently,
there is no conclusive answer for this question. One study showed that
there is cross resistance between some AMPs, and thus pre-exposure to
one peptide can lead to higher resistance to other peptides [189]. In ad-
dition, lfcin B resistant S. aureus bacteria showed mild cross resistance
with Indolicidin and a derivative of magainin (Ala3,13,18-magainin),
while for the same strains no resistance was observed for LL-37 [190].
Induced S. enterica Typhimurium resistant mutants to LL-37,
CNY100HL and Wheat Germ Histones (WGH) showed cross resistance
to the other peptides to a certain extent. Several lines of S. aureus that
are resistant to daptomycin, a lipopeptide, showed a higher resistance
to tPMPs and human neutrophil peptide-1 (hNP-1). However, resis-
tance to PMB was not consistent in most of the lines [67].
However, it has been also shown that there is no cross resistance be-
tweendifferent AMPs. So far, it is suggested that peptides show cross re-
sistance when they share commonmechanisms of action [191], but this
assumption should be further evaluated. In addition, in some cases the
resistance to the AMPs was abolished after removing the AMP [129,
190,192]. This kind of induced resistance is only transient and as a result
of the activation of bacterial systems to environmental changes such
as encountering an AMP. Therefore, it is indeed possible that the use
of AMPs for the treatment of bacterial infections will cause resistance
Fig. 4. TCS activation contributes to AMP resistance. Several TCSs are known to be involved in AMP resistance in Gram-positive and Gram-negative bacteria. In Gram-negative bacteria a
sensor histidine kinase, PhoQ or PmrB, is located on the innermembrane (plasmamembrane) and activated by several environmental signals, some of which are indicated in the cartoon.
Upon activation it undergoes phosphorylation and phosphorylates a response regulator, PhoP and PmrA respectively. The response regulator acts as transcription factor and activates
many genes some of which were found to be related to AMP resistance. There is a crosstalk between these two systems via PmrD, which directly activates PmrA in a PmrB-independent
manner. In Gram-positive bacteria GraRS (ApsSR) is another TCS that is known to be activated by AMPs and is involved in AMP resistance [57,107,160,177,186,187,200].
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that affect cross resistance between AMP, as well as the analysis of the
nature of cross resistance, might allow this problem to be overcome,
so that AMPs can be used as the ﬁrst line treatment for infectious dis-
eases. In addition, combined therapies using two different AMPs or a
regular antibiotic and AMPmight also provide a solution to the cross re-
sistance between AMPs.
7. Summary
In summary, bacteria were found to acquire AMP resistance by
two general mechanisms: (1) induced resistance, by induction of
speciﬁc bacterial systems that contribute to AMP resistance. When
the bacteria are no longer under these conditions the resistance
will vanish. (2) Constitutive resistance which results from genetic
changes. In this reviewwe discussed brieﬂy these two general mech-
anisms which involve:
(i) Extracellular polysaccharide secretion to form capsules that pro-
tect the bacteria from various antimicrobial agents including
AMPs.
(ii) Modifying bacteria surface molecules, such as LTA in Gram-
positive bacteria with the addition of D-alanine. Modiﬁcation of
the LPS moieties: modiﬁcation of the Lipid A by the addition of
glycine, amino sugars such as aminoarabinose, glucosamine
and galactoseamine, dephosphorylation, hydroxylation, addition
of phosphoethanolamine, addition and removal of acyl chains,
and changing the length of O antigen moiety.
(iii) Changes in bacterial surface which can cause alterations in pep-
tide properties, and as such its effect on the bacteria.
(iv) Bioﬁlm formation including the secretion of extra cellularmatrix,
which consists of polysaccharides, proteins and DNA, all of which
form a barrier to AMPs.
(v) Peptide activation of TCSs resulting in gene expression patterns,
which in many cases regulate the above mechanisms, most
of which induce biophysical changes to the bacteria, such assurface rigidity, cell wall thickness, surface charge and mem-
brane ﬂuidity.
Importantly, despite the main concern that bacterial resistance to
administered AMPs might cause resistance to natural AMPs and so sab-
otage the natural immune response, there are indications for only limit-
ed cross resistance between different AMPs.
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